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New insights into drug design are derived from the X-ray crystallographic structures of G protein-coupled receptors
(GPCRs), and the adenosine receptors (ARs) are at the forefront of this effort. The 3D knowledge of receptor binding
and activation promises to enable drug discovery for GPCRs in general, and specifically for the ARs. The predictability
of modeling based on the X-ray structures of the A2AAR has been well demonstrated in the identification, design
and modification of both known and novel AR agonists and antagonists. It is expected that structure-based design
of drugs acting through ARs will provide new avenues to clinically useful agents.
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A large fraction of currently marketed pharmaceuticals
act via G protein-coupled receptors (GPCRs), and un-
derstanding recognition and function of GPCRs at a
precise molecular level is essential for future drug dis-
covery (Jacobson & Costanzi 2012). Action of a drug via
a GPCR is either through direct binding to the receptor
(as orthosteric agonist or antagonist or as allosteric mo-
dulator) or by affecting the levels of the endogenous
transmitter that are available to activate it. Among the
many naturally-occurring extracellular signaling mole-
cules, nucleosides and nucleotides serve to both mo-
dulate biological processes in many organs and tissues
and to maintain homeostasis. In addition to their many in-
tracellular functions and ion channel activation, these ubi-
quitous signaling molecules act outside the cell through
GPCRs. These receptors include eight subtypes of P2Y re-
ceptors (P2YRs), which are all activated by nucleotides but
not nucleosides, and four subtypes of adenosine receptors
(ARs). The increased release and production of extracellu-
lar nucleotides and adenosine, which are localized rather
than systemic, are typically a direct function of stress to
an organ or tissue, such as hypoxia (Chen et al. 2013). The
resulting elevated level of endogenous agonist increases a
tonic activation of one or more of these receptors toCorrespondence: kajacobs@helix.nih.gov
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in any medium, provided the original work is pproduce a protective response. In some cases, such as the
adenosine “halo” surrounding tumor cells (Antonioli et al.
2013), the protective response is undesired clinically, and
in which case an antagonist might be more applicable
therapeutically. Nucleotide action through P2YRs tends to
boost the innate immune system, i.e. the immediate defen-
sive response.
There is renewed interest in developing AR or P2YR
modulators for therapeutic use, due to recent advances
in understanding the related biological processes and in-
creased structural knowledge of the receptors. We and
other labs are exploring structure-activity relationships
(SAR) at ARs and P2YRs, in order to synthesize and cha-
racterize selective agents as pharmacological probes and
as potential therapeutic agents. We emphasize four as-
pects of studying these receptors: 1) design and synthesis
of novel and selective agonists and antagonists to expand
the SAR; 2) structure-function studies of the receptor pro-
teins; 3) exploration of the novel biological role of such re-
ceptors; and 4) conceptualization of future therapeutics.
In this effort, there is a tight coupling of organic synthetic
methodology, molecular modeling, structural biology, and
pharmacology.
Main text and discussion
We are designing more potent and subtype-selective re-
ceptor ligands, based on an understanding of the mo-
lecular recognition in the binding site. New insights intoOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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structures of GPCRs (Jacobson & Costanzi 2012), and
ARs are at the forefront of this effort (Jaakola et al.
2008; Dore et al. 2011; Xu et al. 2011). Although few
compounds that act at these two receptor families are
approved for clinical use, the ARs serve as important
test cases for structure-based ligand design for GPCRs
in general. Since 2008, the availability of X-ray crystallo-
graphic structures of the human A2AAR in complex with
xanthine and non-xanthine antagonists (Jaakola et al.
2008; Dore et al. 2011), has allowed more precise mo-
lecular modeling of the 3 dimensional structures of the
A2AAR and related receptors with other bound ligands.
Recently, a very high resolution structure of an antago-
nist-bound A2AAR (1.8 Å) was reported and shown to
predict allosteric interactions at a site deeper than the or-
thosteric ligand binding region (Liu et al. 2013; Gutiérrez-
de-Terán et al. 2013). The accuracy of many previous AR
modeling and docking studies (Ivanov et al. 2009) is a for-
tuitous result of the close structural similarity of ARs and
rhodopsin, the GPCR used for nearly a decade as the most
closely related protein template for modeling Family A
GPCRs.
In 2011, the first crystal structure of the A2AAR
bound to an agonist, i.e. the highly substituted nucleoside
UK432,097 1 (Figure 1), was determined by Raymond
Stevens and coworkers at Scripps Research Inst. (Xu
et al. 2011), and similar structures of the A2AAR in
complex with adenosine and its mono-substituted de-














































Figure 1 Two of the AR agonists that were co-crystallized with the hu
and A1AR (5).at MRC Laboratory of Molecular Biology in Cambridge,
UK and Heptares Therapeutics (Lebon et al. 2011). The
structures of Lebon et al., which additionally show por-
tions of the second extracellular loop (EL2) not de-
fined in the UK432,097 complex, were determined using
receptors with thermostabilizing point mutations (StaRs).
All agonist-bound A2AAR structures show similar interac-
tions involving the adenine core and the ribose ring with
the receptor. Moreover, the UK432,097 complex is stabi-
lized by multiple H-bonding, van der Waals and hydro-
phobic interactions on extended C2 and N6 substituents.
The agonist interactions within the A2AAR evident in the
X-ray structures are shown below:
Comparison of agonist-bound and inactive conforma-
tions of the A2AAR have largely validated previous ap-
proaches to homology modeling of ARs and indicated
the conformational changes needed for receptor activa-
tion, particularly within the ligand binding region. These
conformational changes include a tightening of hydro-
philic residues in TM3, TM5 and TM7 around the ribose
moiety, which is known to form the “message” portion of
the molecule (Xu et al. 2011). Many of the hydrogen
bonds with ligand found in the agonist-bound A2AAR
structures were predicted by earlier molecular modeling
(Ivanov et al. 2009). Upon binding of nucleoside agonists
to the ARs, unstable water molecules that appear in the
inactive state of the A2AAR (Jaakola et al. 2008; Dore et al.
2011) are expelled from deep in the binding site. The
more hydrophobic adenine moiety, which may be deri-































man A2AAR (1, 2) and agonists selective for the A2AAR (3, 4)
Jacobson In Silico Pharmacology 2013, 1:22 Page 3 of 5
http://www.in-silico-pharmacology.com/content/1/1/22hydrophobic groups that extend further into the EL re-
gion, is considered the “address” portion of adenosine,
with respect to receptor subtype selectivity. Some of the
movements of ELs are specific to accommodate sterically
bulky groups of UK432,097 and are less pronounced in
other agonist-bound A2AAR structures. The implications
for receptor signaling by particular agonists that produce
their own distinct conformational changes of the A2AAR
are not yet known.
Pharmacophore-based searches have yielded ligands
having novel chemotypes, such as diverse heterocyclic
antagonists of the A2AAR, a target for Parkinson’s dis-
ease (de Lera Ruiz et al. 2013). An inactive state struc-
ture of the A2AAR was applied to in silico searches of
diverse chemical libraries to identify antagonists of sev-
eral AR subtypes. This approach has been useful for dis-
covery of antagonists at both the A2AAR (Katritch et al.
2010; Carlsson et al. 2010; van der Horst et al. 2011;
Congreve et al. 2012; Langmead et al. 2012) and the
closely related A1 and A3ARs, by homology. Four sepa-
rate homology models of the human A1AR were built
based on optimization with different bound (known) li-
gands of that subtype, and 2.2 million lead-like com-
pounds were docked in all four models (Kolb et al.
2012). In this study, initially targeting the A1AR, 39 in
silico hits were obtained and subsequently screened in
binding to three AR subtypes, resulting in the following
percent of successful antagonist hits identified: 21% (A1),
38% (A2A) and 36% (A3). Thus, this docking approach is
useful for discovery of hits at the A1AR and at closely
related subtypes. Some of the successful hits bound to
two or three AR subtypes.
Beyond screenings for novel chemotypes, the struc-
tures of the A2AAR have also proved useful to design
improved analogs of the existing ligands. Previous efforts
to develop AR agonists for therapeutic use have faced ef-
ficacy issues and low selectivity, leading to side effects
(Chen et al. 2013). Two agonists of the A3AR that were
first synthesized and characterized biologically in our lab
are already in advanced clinical trials for inflammatory
diseases (IB-MECA, 3) and liver cancer (the 2-chloro
analogue of IB-MECA, CF102). Current or planned trials
of A3AR agonists are for treatment of hepatocellular
cancer, rheumatoid arthritis, psoriasis, dry eye syndrome,
and other inflammatory conditions. Moreover, selective
A1AR agonists are sought as antiseizure agents, analge-
sics and for other neuroprotective functions (Luongo
et al. 2013). Structural insights, enabled by molecular
modeling, have guided the introduction of novel adeno-
sine derivatives as A1 and A3AR agonists. A first step to
validation of the AR agonist modeling approach was to
apply it to the A2AAR, used as template, and then to
extend it to the closely related A1 and A3AR by hom-
ology. Molecular modeling of agonist binding has beenevaluated in light of the crystallographic structure of the
agonist-bound A2AAR and found to predict interactions
of 20 known nucleoside ligands (Deflorian et al. 2012).
Ligand docking and fragment searching are useful for
suggesting new congeners of known AR agonists and an-
tagonists to be synthesized in order to explore distinct
subpockets in the binding site. Our structure-based syn-
thesis of adenosine agonists guided by knowledge of the
X-ray structure treated each region of the nucleoside
using a different approach. For example, binding affin-
ities following distal changes on an extended C2 chain
correlated with predicted interactions in the spatially
permissive EL region (Deflorian et al. 2012). In contrast,
an exploration of the relatively small subpocket of the
agonist-bound A2AAR structure surrounding the 5′ sub-
stituent of ribose yielded novel 5′-amide derivatives,
similar to NECA (Tosh et al. 2012c). The ethyl group of
NECA was replaced with small (MW < 150) but diverse
molecular fragments to complement this subpocket. The
majority of in silico hits that were high ranking energe-
tically (roughly the top 1% of a set of 2000 screened
structures) and tested in binding assays indeed bound
with submicomolar Ki values at the A2AAR. When the
inactive A2AAR structure (3EML) was used for scree-
ning these adenosine analogues with diverse 5′-amide
fragments, the statistical advantage shown in the re-
ceiver operating characteristic (ROC) curve (Figure 2),
clearly evident using the agonist-bound A2AAR struc-
ture (3QAK), disappeared. When an intermediate con-
formational model (agonist-optimized 3EML) was used
for screening, modified from the inactive state through
docking of an agonist and relaxing of side chains, the
ROC predictability was also intermediate. Virtual hits that
more potently inhibited radioligand binding at the A1AR
than the A2AAR were rationalized based on specific
H-bonding interactions with residues of the A1AR as
predicted in the modeling.
A comparison of the ribose binding elements of the
A2AAR with the corresponding amino acid residues in
other subtypes shows more significant variation in the
A3AR than in the A1AR. Affinity (but not efficacy in re-
ceptor activation) of nucleosides at the A3AR seems to
depend more heavily on factors outside the ribose bind-
ing pocket than is the case for other AR subtypes. This
hypothesis is supported by many adenosine analogues
lacking the 5′-amide group entirely, i.e. truncated at the
4′ carbon that still bind potently to the A3AR (Tosh
et al. 2012b). Nevertheless, the tetrahydrofuryl core scaf-
fold of ribose, or an isostere thereof, is still important at
the A3AR as for other AR subtypes.
The latest generation of A3AR receptor agonists contains
a constrained bicyclic (bicyclo[3.1.0]hexane, known as me-
thanocarba) substitution of ribose to maintain a receptor-
preferred North (N) conformation (Tosh et al. 2012a).
Figure 2 Performance of virtual screening of amide fragment derivatives similar to NECA, using three different A2AAR models, reprinted
with permission from Tosh et al. (Tosh et al. 2012c).
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pane rings) in its two isomeric forms, i.e. either (N) or
South (S), as applied to nucleosides was used before any
structural elucidation to interrogate the ribose confor-
mation when bound to an AR (as ribose in adenosine
can readily twist to adopt a range of conformations)
(Jacobson et al. 2000). The adenosine analogue having
a fixed (N) conformation was clearly the more potent
isomer at the A1AR, A2AAR and A3AR, with the greatest
enhancement over (S) occurring at A3AR (155-fold).
Indeed, the predicted (N) ribose conformation was ve-
rified when the agonist-bound A2AAR structures were
determined.
We have explored rigidified (N)-methanocarba C2-ary-
lalkynyl nucleoside analogues, such as MRS5698 4, that
are highly selective A3AR agonists. The very high A3AR
selectivity (typically ~10,000-fold) in this series of C2-
arylalkynyl (N)-methanocarba nucleosides was consistent
with a predicted outward movement of the portion of
TM2 near the EL region of the A3AR, in order to pre-
serve hydrogen-bonding interactions with conserved res-
idues in TMs 3, 5, and 7 that lock the adenosine moiety
in its deeper binding pocket. This outward movement of
TM2, which is justified based on other activated GPCR
structures (opsin and β2-adrenergic receptor) is not
likely to occur in the A2AAR, because the EL region
of this AR subtype is conformationally constrained by
four disulfide bridges.
A1AR agonist MRS5474 5 also contains a constrained
bicyclic substitution of ribose to maintain a receptor-
preferred North (N) conformation (Tosh et al. 2012b).
MRS5474 has in vivo anti-convulsant activity without
typical rotorod toxicity observed for standard A1AR ago-
nists, which are known to produce intense cardiovascu-
lar depression. The N6-dicyclopropylmethyl substitution
was selected by screening (in binding assays of the syn-
thetic analogues), in the truncated, methanocarba series,
many alkyl/aryl groups known to promote A1AR agon-
ism in the ribose series (Tosh et al. 2012b). This particu-
lar N6 group appears to be a structural sweet spot, inthat it maintains selectivity and full efficacy. The very
tight fit in the N6 region in receptor docking has been
analyzed through homology modeling of the human
A1AR, based on the agonist-bound A2AAR structure (Xu
et al. 2011). Deletion of an otherwise important recogni-
tion element (H-bonding groups at the 5′ position) is
compensated by a specific N6 substitution in MRS5474.
Novel fluorescent and radiolabeled probes and mul-
tivalent conjugates of strategically functionalized AR li-
gands have also been designed with the aid of molecular
modeling (Kozma et al. 2013). Such high affinity ligands
containing reporter groups are useful tools for the charac-
terization of receptors and their oligomeric assemblies.
For example, adenosine agonist binding to the heterodi-
mers formed between the A2AAR and D2 dopamine re-
ceptor can be followed in real time using such a conjugate
(Fernández-Dueñas et al. 2012). The interaction of the
fluorophore of a given fluorescent chemical probe with
the outer portions of the receptor, mainly distal interac-
tions with functional groups on the receptor, may have a
major influence on its affinity and selectivity. Thus, the
pharmacological profile of the functionalized congener
that serves as precursor of the fluorescent ligand is not
always predictive of the properties of the final conjugate,
and GPCR molecular modeling can provide insight into
this phenomenon. One such example is a fluorescent
agonist of the P2Y6R that was greatly enhanced in potency
and selectivity by the addition of an AlexaFluor488 moiety
at the end of a flexible chain (Jayasekara et al. 2013). Ac-
cording to receptor modeling, this fluorophore did not es-
cape the outer environment, i.e. the ELs of the P2Y6R
where they are predicted to anchor to specific sites. In this
case, the closer template for homology modeling for the
P2YRs was judged to be the CXCR4 structure, rather than
the A2AAR structure.
Conclusions
Thus, the 3D knowledge of receptor binding and activa-
tion promises to enable drug discovery for GPCRs in
general, and specifically for the ARs. The predictability
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has been well demonstrated in the design and modifica-
tion of both known and novel AR agonists and antago-
nists. In silico screening by docking of chemical libraries
to these new structures and to closely related receptor
homology models has been validated. It is expected that
structure-based design of drugs acting through ARs will
provide new avenues to clinically useful agents.
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